ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
حول Alnylam Pharmaceuticals, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
اقرأ المزيد
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
History
The company is a spin-off from the Max Planck Institute for Biophysical Chemistry. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders, and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy. In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
On October 10, 2018, Alnylam appoints Margaret Hamburg to Board of Directors. Prior to this, from May 2009 to April 2015, she serves as Commissioner of the U.S. Food and Drug Administration (FDA).
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.
In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.
In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.
Products
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.
Patisiran
In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).
In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
FDA on patisiran for cardiomyopathy
In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA. The committee meeting chose to deny approval for the treatment of cardiomyopathy of ATTR amyloidosis with patisiran. Note that while patisiran was denied for the indication of cardiomyopathy, it remains an FDA approved treatment for polyneuropathy.
Vutrisiran
Alnylam went on to pursue the development of vutrisiran, which received FDA approval in 2022 and accounted for the majority of reported profit compared to patisiran/Onpattro in 2025.
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
ALNY لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
ALNY مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
ALNY توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
- شراء قوي 8 21,6%
- شراء 21 56,8%
- احتفاظ 8 21,6%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
24 محللين · 2026-08-14سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $1.21 | $1.59 | -0.38% |
| 31 مارس، 2026 | $1.51 | $0.98 | 0.53% |
| 31 ديسمبر، 2025 | $0.82 | $1.15 | -0.33% |
| 30 سبتمبر، 2025 | $2.11 | $0.76 | 1.3% |
| 30 يونيو، 2025 | $-0.51 | $-0.73 | 0.22% |
| 31 مارس، 2025 | $-0.44 | $-1.03 | 0.59% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
الميزانية العمومية 23
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
التدفق النقدي 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
السيولة والملاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
معدلات النمو 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
قائمة الدخل 17
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
الميزانية العمومية 22
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
التدفق النقدي 12
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
السيولة والملاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
التقييم (آخر 12 شهرًا) 10
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| هامش الربح التشغيلي % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| صافي الدخل | $314M | $-278M | $-440M | $-1.13B | $-853M |
| EPS المخفف | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| النسبة الحالية | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| النسبة السريعة | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $465M | $-43M | $42M | $-613M | $-718M |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 877 مقدمي إقرار · $27.1B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 99 (-11 مقابل الربع السابق) | 77 (-68 مقابل الربع السابق) | 328 (+4 مقابل الربع السابق) | 259 (+4 مقابل الربع السابق) | +15.9M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| Capital World Investors | $3354715611 | 11144846 | 12,36% | الأسهم |
| FMR LLC | $3108157652 | 10325076 | 11,45% | الأسهم |
| Capital Research Global Investors | $2935115324 | 9750699 | 10,81% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1968251542 | 6538390 | 7,25% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $1815053762 | 6029478 | 6,69% | الأسهم |
| STATE STREET CORP | $1070369060 | 3555689 | 3,94% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $686853582 | 2288725 | 2,53% | الأسهم |
| NORGES BANK | $683883867 | 2271813 | 2,52% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $614923915 | 2042733 | 2,26% | الأسهم |
| Dodge & Cox | $588631955 | 1955393 | 2,17% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $564713315 | 1875937 | 2,08% | الأسهم |
| AMERICAN CENTURY COMPANIES INC | $558098292 | 1853956 | 2,06% | الأسهم |
| TWO SIGMA ADVISERS, LP | $450362484 | 1132560 | 1,66% | الأسهم |
| Clearbridge Investments, LLC | $379142285 | 1259483 | 1,40% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269059154 | 893795 | 0,99% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $259723265 | 862782 | 0,96% | الأسهم |
| Deep Track Capital, LP | $248349750 | 825000 | 0,91% | الأسهم |
| Qube Research & Technologies Ltd | $240437176 | 798715 | 0,89% | الأسهم |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219642021 | 729635 | 0,81% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $176408397 | 586016 | 0,65% | الأسهم |
| LOOMIS SAYLES & CO L P | $170456431 | 566244 | 0,63% | الأسهم |
| BAILLIE GIFFORD & CO | $165849468 | 550940 | 0,61% | الأسهم |
| ROYAL BANK OF CANADA | $154998000 | 514893 | 0,57% | الأسهم |
| Polar Capital Holdings Plc | $145322534 | 482751 | 0,54% | الأسهم |
| Paradigm Biocapital Advisors LP | $144494400 | 480000 | 0,53% | الأسهم |
| D. E. Shaw & Co., Inc. | $129533209 | 430300 | 0,48% | عقد خيار الشراء |
| FIRST TRUST ADVISORS LP | $126894361 | 421534 | 0,47% | الأسهم |
| Swiss National Bank | $112609302 | 374080 | 0,41% | الأسهم |
| WELLS FARGO & COMPANY/MN | $111381100 | 370000 | 0,41% | عقد خيار الشراء |
| BlackRock, Inc. | $102807465 | 341519 | 0,38% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $100618073 | 334246 | 0,37% | الأسهم |
| Sumitomo Mitsui Trust Group, Inc. | $97948840 | 325379 | 0,36% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97804647 | 324900 | 0,36% | عقد خيار الشراء |
| Legal & General Group Plc | $97467493 | 323780 | 0,36% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $95125781 | 316001 | 0,35% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $94687695 | 314546 | 0,35% | الأسهم |
| Candriam S.C.A. | $94586456 | 314512 | 0,35% | الأسهم |
| D. E. Shaw & Co., Inc. | $93229593 | 309702 | 0,34% | الأسهم |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90367000 | 300193 | 0,33% | الأسهم |
| DEUTSCHE BANK AG\ | $89849026 | 298472 | 0,33% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88641294 | 294460 | 0,33% | الأسهم |
| Pictet Asset Management Holding SA | $83257214 | 278613 | 0,31% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $81586054 | 271023 | 0,30% | الأسهم |
| GILDER GAGNON HOWE & CO LLC | $80992374 | 269051 | 0,30% | الأسهم |
| CONGRESS ASSET MANAGEMENT CO | $79983972 | 265701 | 0,29% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $77578441 | 257710 | 0,29% | الأسهم |
| California Public Employees Retirement System | $76477575 | 254053 | 0,28% | الأسهم |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75974872 | 252383 | 0,28% | الأسهم |
| Korea Investment CORP | $74553090 | 247660 | 0,27% | الأسهم |
| Woodline Partners LP | $74138270 | 246282 | 0,27% | الأسهم |
| Squarepoint Ops LLC | $70440719 | 233999 | 0,26% | الأسهم |
| TD Asset Management Inc | $70349507 | 233696 | 0,26% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65136061 | 196863 | 0,24% | الأسهم |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64296696 | 213589 | 0,24% | الأسهم |
| National Pension Service | $59692744 | 198295 | 0,22% | الأسهم |
| PINEBRIDGE INVESTMENTS LLC | $58914280 | 195709 | 0,22% | الأسهم |
| Robeco Institutional Asset Management B.V. | $56618929 | 188084 | 0,21% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53824164 | 178800 | 0,20% | عقد خيار البيع |
| VICTORY CAPITAL MANAGEMENT INC | $52030628 | 172842 | 0,19% | الأسهم |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50772924 | 168664 | 0,19% | الأسهم |
| RHUMBLINE ADVISERS | $49844185 | 165579 | 0,18% | الأسهم |
| Life Cycle Investment Partners Ltd | $49797587 | 165424 | 0,18% | الأسهم |
| ANTIPODES PARTNERS Ltd | $49228339 | 163533 | 0,18% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47228883 | 157223 | 0,17% | الأسهم |
| CAPITAL FUND MANAGEMENT S.A. | $46931781 | 155904 | 0,17% | الأسهم |
| Assenagon Asset Management S.A. | $46868866 | 155695 | 0,17% | الأسهم |
| Vinva Investment Management Ltd | $45487381 | 154972 | 0,17% | الأسهم |
| JANUS HENDERSON GROUP PLC | $43671202 | 132000 | 0,16% | الأسهم |
| Hudson Bay Capital Management LP | $42204406 | 140200 | 0,16% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $41059106 | 136395 | 0,15% | الأسهم |
| ProShare Advisors LLC | $38686569 | 128514 | 0,14% | الأسهم |
| GOLDMAN SACHS GROUP INC | $37029700 | 123010 | 0,14% | الأسهم |
| LMR Partners LLP | $35881572 | 119196 | 0,13% | الأسهم |
| Man Group plc | $35798187 | 118919 | 0,13% | الأسهم |
| HSBC HOLDINGS PLC | $35754282 | 120600 | 0,13% | عقد خيار البيع |
| SCS Capital Management LLC | $34783715 | 115549 | 0,13% | الأسهم |
| AVIVA PLC | $34477568 | 114532 | 0,13% | الأسهم |
| Davern Capital Partners, LP | $34041978 | 113085 | 0,13% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33770750 | 112184 | 0,12% | الأسهم |
| Longaeva Partners L.P. | $33191869 | 110261 | 0,12% | الأسهم |
| 683 Capital Management, LLC | $32360725 | 107500 | 0,12% | عقد خيار البيع |
| MARSHALL WACE, LLP | $32215929 | 107019 | 0,12% | الأسهم |
| HighTower Advisors, LLC | $31621666 | 105045 | 0,12% | الأسهم |
| Bridgewater Associates, LP | $29977772 | 99584 | 0,11% | الأسهم |
| Prosight Management, LP | $29525022 | 98080 | 0,11% | الأسهم |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28956123 | 96408 | 0,11% | الأسهم |
| Andra AP-fonden | $28685436 | 86697 | 0,11% | الأسهم |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28376894 | 94266 | 0,10% | الأسهم |
| AMERIPRISE FINANCIAL INC | $28191159 | 93649 | 0,10% | الأسهم |
| BARCLAYS PLC | $27979234 | 92945 | 0,10% | الأسهم |
| TREMBLANT CAPITAL GROUP | $27977728 | 92940 | 0,10% | الأسهم |
| FIL Ltd | $27652616 | 91860 | 0,10% | الأسهم |
| Balyasny Asset Management L.P. | $26945195 | 89510 | 0,10% | الأسهم |
| Caisse de depot et placement du Quebec | $25812720 | 85748 | 0,10% | الأسهم |
| Mitsubishi UFJ Trust & Banking Corp | $24911136 | 82753 | 0,09% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $24661883 | 81925 | 0,09% | الأسهم |
| CITADEL ADVISORS LLC | $24564048 | 81600 | 0,09% | عقد خيار الشراء |
| VANGUARD GROUP INC | $24356460 | 61251 | 0,09% | الأسهم |
| NEOS Investment Management LLC | $23562822 | 78274 | 0,09% | الأسهم |
| JONES FINANCIAL COMPANIES LLLP | $23444213 | 80462 | 0,09% | الأسهم |
المطلعون على الشركة 41 من المطلعين · مسؤولون 1 · مديرون 13
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | 6 إبريل، 2026 S | 9443 | 0 | 14 | $-1274343 |
| Colleen F Reitan | مدير | 20 مايو، 2026 A | 1446 | 0 | 0 | $0 |
| Charles Elliott Sigal | مدير | 20 مايو، 2026 A | 1446 | 0 | 0 | $0 |
| Stuart A Arbuckle | مدير | 20 مايو، 2026 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | مدير | 20 مايو، 2026 A | 1446 | 0 | 0 | $0 |
| Amy Schulman | مدير | 20 مايو، 2026 A | 24049 | 0 | 0 | $0 |
| Dennis A Ausiello | مدير | 20 مايو، 2026 A | 1582 | 0 | 0 | $0 |
| Margaret A Hamburg | مدير | 20 مايو، 2026 A | 1582 | 0 | 0 | $0 |
| KELLOGG PETER N | مدير | 20 مايو، 2026 A | 1446 | 0 | 0 | $0 |
| David E I Pyott | مدير | 20 مايو، 2026 A | 1582 | 0 | 0 | $0 |
| Victor J Dzau | مدير | 21 يونيو، 2012 A | — | 0 | 0 | $0 |
| Peter Barrett | مدير | 1 يونيو، 2006 A | 5293 | 0 | 0 | $0 |
| John E Berriman | مدير | 8 يونيو، 2005 A | 2475 | 0 | 0 | $0 |
| Christoph H Westphal | مدير | 3 يونيو، 2004 C | 2409970 | 0 | 0 | $0 |
| Sanofi | مالك 10% | 31 مايو، 2017 P | 10554134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | مالك 10% | 23 فبراير، 2016 S | 4896716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | مالك 10% | 3 يونيو، 2004 C | 2409970 | 0 | 0 | $0 |
| CHP II LP | مالك 10% | 27 مايو، 2004 P | 232500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | 10 أغسطس، 2018 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | 10 أغسطس، 2018 A | 9030 | 0 | 0 | $0 |
| John Maraganore | — | 10 أغسطس، 2018 A | 151297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | 9 مارس، 2018 M | 140795 | 0 | 0 | $0 |
| Michael Mason | — | 4 يناير، 2018 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | 29 ديسمبر، 2017 M | 14500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | 20 ديسمبر، 2017 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | 20 ديسمبر، 2016 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 19 نوفمبر، 2015 G | 306996 | 0 | 0 | $0 |
| Marsha Fanucci | — | 1 يونيو، 2015 A | 10000 | 0 | 0 | $0 |
| Steven M Paul | — | 1 يونيو، 2015 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | 1 يونيو، 2015 A | — | 0 | 0 | $0 |
| John K Clarke | — | 1 يونيو، 2015 A | 2091868 | 0 | 0 | $0 |
| Kevin P Starr | — | 1 يونيو، 2015 A | — | 0 | 0 | $0 |
| Laurence Reid | — | 19 مايو، 2014 M | 3905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | 8 ديسمبر، 2010 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | 8 ديسمبر، 2010 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | 18 يونيو، 2010 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | 2 يونيو، 2010 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | 11 يونيو، 2009 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | 9 ديسمبر، 2008 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | 7 ديسمبر، 2005 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | 3 يونيو، 2004 C | 18745 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 2 حيازتان
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 إيداعات | 14 فبراير، 2007 | — | إيداع أولي | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | 15 فبراير، 2006 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 150 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 3,25% | 53807 SH | 8 أغسطس، 2026 | يومي |
| NUMG · Nushares ETF Trust | 3,23% | 36910 NS | 30 إبريل، 2026 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3,19% | 10523 NS | 31 مايو، 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,79% | 3791 NS | 31 مايو، 2026 | N-PORT |
| IBB · iShares Trust | 2,21% | 976319 SH | 8 أغسطس، 2026 | يومي |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2,01% | 3468 NS | 30 إبريل، 2026 | N-PORT |
| BIB · ProShares Trust | 2,01% | 4904 NS | 31 مايو، 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,99% | 7268 SH | 8 أغسطس، 2026 | يومي |
| FDG · AMERICAN CENTURY ETF TRUST | 1,94% | 26515 NS | 31 مايو، 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,40% | 824 NS | 30 إبريل، 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1,29% | 15623 NS | 30 إبريل، 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,24% | 2379 NS | 30 إبريل، 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,14% | 1954 NS | 31 مايو، 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 1,08% | 966 NS | 30 إبريل، 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,90% | 15151 NS | 30 إبريل، 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0,89% | 35072 NS | 30 إبريل، 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0,88% | 1022888 SH | 8 أغسطس، 2026 | يومي |
| IWP · iShares Trust | 0,82% | 770414 SH | 8 أغسطس، 2026 | يومي |
| JOET · Virtus ETF Trust II | 0,80% | 6062 NS | 30 إبريل، 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0,76% | 613330 NS | 31 مايو، 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,66% | 60901 NS | 30 إبريل، 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,59% | 398693 SH | 8 أغسطس، 2026 | يومي |
| FFLG · FIDELITY COVINGTON TRUST | 0,58% | 11032 NS | 30 إبريل، 2026 | N-PORT |
| QNXT · iShares Trust | 0,54% | 699 SH | 8 أغسطس، 2026 | يومي |
| USMV · iShares Trust | 0,47% | 527555 SH | 8 أغسطس، 2026 | يومي |
| IYH · iShares Trust | 0,47% | 79894 SH | 8 أغسطس، 2026 | يومي |
| VXF · VANGUARD INDEX FUNDS | 0,45% | 1532109 SH | 8 أغسطس، 2026 | يومي |
| UPSD · ETF Series Solutions | 0,44% | 1435 NS | 30 إبريل، 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0,43% | 4118 NS | 31 مايو، 2026 | N-PORT |
| QFLR · Innovator ETFs Trust | 0,39% | 6430 NS | 30 إبريل، 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,39% | 2893468 SH | 8 أغسطس، 2026 | يومي |
| IMCG · iShares Trust | 0,38% | 72243 SH | 8 أغسطس، 2026 | يومي |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,38% | 10723 NS | 30 إبريل، 2026 | N-PORT |
| ESMV · iShares Trust | 0,35% | 128 SH | 8 أغسطس، 2026 | يومي |
| SDG · iShares Trust | 0,33% | 2658 SH | 8 أغسطس، 2026 | يومي |
| SMIZ · Zacks Trust | 0,31% | 2688 NS | 31 مايو، 2026 | N-PORT |
| ESLG · Strategy Shares | 0,31% | 196 NS | 30 إبريل، 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,31% | 112 NS | 30 إبريل، 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,30% | 305 NS | 30 إبريل، 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,28% | 94 NS | 31 مايو، 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,26% | 404 NS | 30 إبريل، 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0,24% | 2252 NS | 30 إبريل، 2026 | N-PORT |
| ESUM · Strategy Shares | 0,23% | 1141 NS | 30 إبريل، 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,23% | 45231 NS | 30 إبريل، 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,22% | 15559 NS | 30 إبريل، 2026 | N-PORT |
| QCLR · Global X Funds | 0,21% | 27 NS | 30 إبريل، 2026 | N-PORT |
| QYLG · Global X Funds | 0,21% | 953 NS | 30 إبريل، 2026 | N-PORT |
| IWR · iShares Trust | 0,21% | 542695 SH | 8 أغسطس، 2026 | يومي |
| QRMI · Global X Funds | 0,21% | 108 NS | 30 إبريل، 2026 | N-PORT |
| QYLD · Global X Funds | 0,20% | 54832 NS | 30 إبريل، 2026 | N-PORT |